{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:07:13Z","timestamp":1791295633453,"version":"4.1.0"},"reference-count":37,"publisher":"Impact Journals, LLC","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,9,29]]},"DOI":"10.18632\/oncotarget.5069","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T17:43:03Z","timestamp":1443548583000},"page":"28327-28340","source":"Crossref","is-referenced-by-count":35,"title":["Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure"],"prefix":"10.18632","volume":"6","author":[{"given":"Pierre-Emmanuel","family":"Colombo","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Institut de Canc\u00e9rologie de Montpellier, Montpellier, France"},{"name":"Institut de Recherche en Canc\u00e9rologie de Montpellier, Universit\u00e9 Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"du Manoir","sequence":"additional","affiliation":[{"name":"Institut de Recherche en Canc\u00e9rologie de Montpellier, Universit\u00e9 Montpellier, Montpellier, France"},{"name":"INSERM U1194, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Orsetti","sequence":"additional","affiliation":[{"name":"Institut de Recherche en Canc\u00e9rologie de Montpellier, Universit\u00e9 Montpellier, Montpellier, France"},{"name":"INSERM U1194, Montpellier, France"},{"name":"Institut de Canc\u00e9rologie de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Bras-Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Institut de Recherche en Canc\u00e9rologie de Montpellier, Universit\u00e9 Montpellier, Montpellier, France"},{"name":"INSERM U1194, Montpellier, France"},{"name":"Institut de Canc\u00e9rologie de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario B.","family":"Lambros","sequence":"additional","affiliation":[{"name":"Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"MacKay","sequence":"additional","affiliation":[{"name":"Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Tuan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Institut de Recherche en Canc\u00e9rologie de Montpellier, Universit\u00e9 Montpellier, Montpellier, France"},{"name":"INSERM U1194, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Boissi\u00e8re","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Recherche Translationnelle, Institut de Canc\u00e9rologie de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Pourquier","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institut de Canc\u00e9rologie de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bibeau","sequence":"additional","affiliation":[{"name":"Department of Pathology, Institut de Canc\u00e9rologie de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge S.","family":"Reis-Filho","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Theillet","sequence":"additional","affiliation":[{"name":"Institut de Recherche en Canc\u00e9rologie de Montpellier, Universit\u00e9 Montpellier, Montpellier, France"},{"name":"INSERM U1194, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,7,31]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"2","first-page":"v23","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21 Suppl 5","author":"Parma","year":"2010","journal-title":"Ann Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.critrevonc.2013.08.017","article-title":"Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer","volume":"89","author":"Theillet","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejso.2008.01.005","article-title":"Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients","volume":"35","author":"Fabbro","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"5","first-page":"151","article-title":"Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications","volume":"27","author":"Shih Ie","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"6","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1200\/JCO.2008.18.1107","article-title":"New insights into the pathogenesis of serous ovarian cancer and its clinical impact","volume":"26","author":"Drapkin","year":"2008","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Goh","year":"2012","journal-title":"JAMA"},{"key":"8","doi-asserted-by":"crossref","first-page":"e80023","DOI":"10.1371\/journal.pone.0080023","article-title":"Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations","volume":"8","author":"Izarzugaza","year":"2013","journal-title":"PLoS One"},{"key":"9","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ymthe.2004.08.013","article-title":"Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer","volume":"10","author":"Dawson","year":"2004","journal-title":"Mol Ther"},{"key":"10","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Levine","year":"2013","journal-title":"Nat Commun"},{"key":"11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ejca.2004.01.009","article-title":"Clonogenic assay with established human tumour xenografts: correlation oftoactivity as a basis for anticancer drug discovery","volume":"40","author":"Burger","year":"2004","journal-title":"Eur J Cancer"},{"key":"12","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-07-0078","article-title":"A new model of patient tumor-derived breast cancer xenografts for preclinical assays","volume":"13","author":"Auger","year":"2007","journal-title":"Clin Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.molonc.2013.11.010","article-title":"Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse","volume":"8","author":"Bras-Goncalves","year":"2014","journal-title":"Mol Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10549-012-2226-y","article-title":"Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors","volume":"135","author":"Kapoun","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"15","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1186\/bcr3095","article-title":"Molecular profiling of patient-derived breast cancer xenografts","volume":"14","author":"Decraene","year":"2012","journal-title":"Breast Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0233","article-title":"A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer","volume":"10","author":"Rajeshkumar","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/bcr3355","article-title":"Patient-derived breast tumor xenografts facilitating personalized cancer therapy","volume":"15","author":"Pietenpol","year":"2013","journal-title":"Breast Cancer Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/nm.2454","article-title":"Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes","volume":"17","author":"Lin","year":"2011","journal-title":"Nat Med"},{"key":"20","article-title":"Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts","author":"Assayag","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"21","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1158\/0008-5472.CAN-12-4704","article-title":"ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program","volume":"73","author":"Bertucci","year":"2013","journal-title":"Cancer Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1078-0432.CCR-09-2878","article-title":"Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy","volume":"16","author":"English","year":"2010","journal-title":"Clin Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1158\/1078-0432.CCR-08-0138","article-title":"Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers","volume":"14","author":"Soong","year":"2008","journal-title":"Clin Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/CAD.0b013e3283300a29","article-title":"Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts","volume":"21","author":"Arvelo","year":"2010","journal-title":"Anticancer Drugs"},{"key":"25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1078-0432.CCR-10-2224","article-title":"The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer","volume":"17","author":"Pintilie","year":"2011","journal-title":"Clin Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1158\/1078-0432.CCR-06-0113","article-title":"Anplatform for translational drug development in pancreatic cancer","volume":"12","author":"Cusatis","year":"2006","journal-title":"Clin Cancer Res"},{"key":"27","first-page":"3","article-title":"Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer","volume":"10","author":"Garrido-Laguna","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.eururo.2010.11.043","article-title":"Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma","volume":"59","author":"Tamboli","year":"2011","journal-title":"Eur Urol"},{"key":"29","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/1078-0432.CCR-09-3066","article-title":"Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and\/or metastatic tumors","volume":"16","author":"Laurent","year":"2010","journal-title":"Clin Cancer Res"},{"key":"30","first-page":"e258","article-title":"Patient-derived xenograft models in gynecologic malignancies","author":"Haluska","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"31","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-13-2611","article-title":"Tumorgrafts assurrogates for women with ovarian cancer","volume":"20","author":"Enderica-Gonzalez","year":"2014","journal-title":"Clin Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.molonc.2014.01.008","article-title":"Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts","volume":"8","author":"Cook","year":"2014","journal-title":"Mol Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.2373","article-title":"Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer","volume":"5","author":"Steg","year":"2014","journal-title":"Oncotarget"},{"key":"34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Vandin","year":"2013","journal-title":"Nature"},{"key":"35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nature13556","article-title":"Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity","volume":"514","author":"Altrock","year":"2014","journal-title":"Nature"},{"key":"36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/path.4230","article-title":"Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling","volume":"231","author":"Tone","year":"2013","journal-title":"J Pathol"},{"key":"37","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1593\/neo.13922","article-title":"Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics","volume":"15","author":"Chang","year":"2013","journal-title":"Neoplasia"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T15:41:22Z","timestamp":1594827682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,31]]},"references-count":37,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2015,9,29]]}},"alternative-id":["5069","26334103"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5069","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,31]]}}}